Amendments to the Claims

1. (Original) A pharmaceutical composition comprising amorphous cefditoren pivoxil and a sugar ester fatty acid, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sugar ester fatty acid while amorphous cefditoren pivoxil maintains its particle state.

2. (Original) The pharmaceutical composition according to claim 1, which contains 0.1 to 100 mg of the sugar ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

3. (Previously presented) The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable polymer.

4. (Original) The pharmaceutical composition according to claim 3, wherein the polymer is one or more water-soluble high polymers selected from hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

5. (Previously presented) The pharmaceutical composition according to claim 3, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

6. (Previously presented) The pharmaceutical composition according to claim 1, which further comprises one or more pharmaceutically acceptable additives.

7. (Previously presented) The pharmaceutical composition according to claim 2, which further comprises a pharmaceutically acceptable polymer.

8. (Previously presented) The pharmaceutical composition according to claim 7, wherein the polymer is one or more water-soluble high polymers selected from

hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

9. (Previously presented) The pharmaceutical composition according to claim 4, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

10. (Previously presented) The pharmaceutical composition according to claim 7, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

11. (Previously presented) The pharmaceutical composition according to claim 8, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

12. (Previously presented) The pharmaceutical composition according to claim 2, which further comprises one or more pharmaceutically acceptable additives.

13. (Previously presented) The pharmaceutical composition according to claim 3, which further comprises one or more pharmaceutically acceptable additives.

14. (Previously presented) The pharmaceutical composition according to claim 4, which further comprises one or more pharmaceutically acceptable additives.

15. (Previously presented) The pharmaceutical composition according to claim 7, which further comprises one or more pharmaceutically acceptable additives.

16. (Previously presented) The pharmaceutical composition according to claim 8, which further comprises one or more pharmaceutically acceptable additives.

17. (Previously presented) The pharmaceutical composition according to claim 9, which further comprises one or more pharmaceutically acceptable additives.

18. (Previously presented) The pharmaceutical composition according to claim 10, which further comprises one or more pharmaceutically acceptable additives.

19. (Previously presented) The pharmaceutical composition according to claim 11, which further comprises one or more pharmaceutically acceptable additives.

20. (New) A pharmaceutical composition comprising particles having amorphous cefditoren pivoxil present in an interior portion of said particles and a sugar ester fatty acid present in an exterior portion of said particles.

21. (New) The pharmaceutical composition of claim 20, wherein the sugar ester fatty acid has a hydrophilic to lipophilic balance (HLB) value greater than 10.

22. (New) The pharmaceutical composition of claim 20, wherein said sugar ester fatty acid has an HLB value in a range of from 11 to 20.

23. (New) The pharmaceutical composition of claim 20, further comprising a pharmaceutically acceptable polymer.

24. (New) The pharmaceutical composition of claim 23, wherein said pharmaceutically acceptable polymer includes at least one polymer selected from among hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

25. (New) A pharmaceutical composition according to claim 20, in a dose form containing from about 300 to 800 milligrams of amorphous cefditoren pivoxil.

26. (New) The pharmaceutical composition of claim 20 in a tableted dose form.

27. (New) A method of making a pharmaceutical composition containing cefditoren pivoxil, said method comprising mixing or wet-granulating particles containing amorphous cefditoren pivoxil with a sugar ester fatty acid while maintaining a particulate character of said amorphous cefditoren pivoxil.

28. (New) The method of claim 27, further comprising mixing the particles containing amorphous cefditoren pivoxil with a pharmaceutically acceptable polymer.

29. (New) The method according to claim 28, wherein said pharmaceutically acceptable polymer includes a polymer selected from among hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

30. (New) The method of claim 27, further comprising tabletting said composition.